



Clár Sláinte Náisiúnta do Mhná & do Naíonáin
Feidhmeannacht na Seirbhíse Sláinte, Aonad 7A, Áras
Dargan, An Ceantar Theas, Baile Átha Cliath 8
T: 076 695 9991

National Women and Infants Health Programme
Health Service Executive, Unit 7A, The Dargan Building,
Heuston South Quarter, Dublin 8
T: 076 695 9991

29th September 2020

Deputy Nolan,
Dáil Éireann,
Leinster House
Dublin 2

PQ Ref 23807/20 To ask the Minister for Health if the HSE has been notified of significant adverse outcomes including hospitalisation of women that were prescribed mifepristone and misoprostol in 2019 and to date in 2020.

Dear Deputy Nolan,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question, which you submitted to the Minister for Health for response. I have examined the matter and the following outlines the position.

There is no national reporting system in place in relation to adverse outcomes specific to medication used in the provision of termination of pregnancy services. From the commencement of this healthcare service in 2019, all nineteen maternity services provide care to women that may be required arising from a complication associated with the provision of a termination.

This care is provided by the 19 maternity services irrespective of whether the termination service was provided in the community by general practitioners or provided in a hospital. As such any medical complications that arise in relation to the provision of termination of pregnancy services are managed at local level in line with clinical guidelines and protocols.

I trust this clarifies the matter.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Mary-Jo Biggs'.

Mary-Jo Biggs, General Manager, National Women and Infants Health Programme